Synthesis and biological evaluation of potent αvβ3-integrin receptor antagonists

Nuclear Medicine and Biology

Volumn 33, Issue 8, 2006, Pages 953-961

  Dijkgraaf, Ingrid ^a,b   Kruijtzer, John A W ^b   Frielink, Cathelijne ^a   Soede, Annemieke C ^a   Hilbers, Hans W ^b   Oyen, Wim J G ^a   Corstens, Frans H M ^a   Liskamp, Rob M J ^b   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

v 3 Integrin; 111In; Peptidomimetic; Peptoid; RGD peptide

Indexed keywords

ALPHA INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; INDIUM 111;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; EVALUATION; FEMALE; GENE TARGETING; IC 50; ISOTOPE LABELING; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; RECEPTOR BINDING;

ANIMALS; DRUG STABILITY; FEMALE; INDIUM RADIOISOTOPES; INTEGRIN ALPHAVBETA3; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33751255965     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.08.008     Document Type: Article

References (32)

1. Ruoslathi E., and Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 238 (1987) 491-497
2. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1508
3. Bishop G.G., McPherson J.A., Sanders J.M., Hesselbacher S.E., Feldman M.J., McNamara C.A., et al. Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 103 (2001) 1906-1911
4. Albelda S.M., Smith C.W., and Ward P.A. Adhesion molecules and inflammatory injury. FASEB J 8 (1994) 504-512
5. Storgard C.M., Stupack D.G., Jonczyk A., Goodman S.L., Fox R.I., and Cheresh D.A. Decreased angiogenesis and arthritic disease in rabbits treated with an alpha(v)beta(3) antagonist. J Clin Invest 103 (1999) 47-54
6. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci 54 (1998) 541-548
7. Eliceiri B.P., and Cheresh D.A. The role of alpha(v) integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103 (1999) 1227-1230
8. Smith J.W., and Cheresh D.A. The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the β subunit. J Biol Chem 263 (1988) 18726-18731
9. 3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 36 (1997) 1374-1389
10. Aumailley M., Gurrath M., Muller G., Calvete J., Timpl R., and Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 291 (1991) 50-54
11. Gurrath M., Muller G., Kessler H., Aumailley M., and Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RDG peptides. Eur J Biochem 210 (1992) 911-921
12. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40 (1999) 1061-1071
13. 3-octreotide by conjugation with carbohydrates. Bioconjug Chem 13 (2002) 1021-1030
14. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15 (2004) 61-69
15. 18F]Galacto-RGD. PloS Med 2 (2005) e70
16. de Haan E.C., Wauben M.H.M., Grosfeld-Stulemeyer M.C., Kruijtzer J.A.W., Liskamp R.M.J., and Moret E.E. Major histocompatibility complex class II binding characteristics of peptoid-peptide hybrids. Bioorg Med Chem 10 (2002) 1939-1945
17. 3 integrin antagonists. J Med Chem 42 (1999) 3033-3040
18. Simon R.J., Kania R.S., Zuckermann R.N., Huebner V.D., Jewell D.A., Banville S., et al. Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci U S A 89 (1992) 9367-9371
19. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296 (2002) 2404-2407
20. Kruijtzer J.A.W., Hofmeyer L.J.F., Heerma W., Versluis C., and Liskamp R.M.J. Solid-phase synthesis of peptoids using Fmoc-protected N-substituted glycines: the synthesis of (retro)peptoids of Leu-enkephalin and substance P. Chem Eur J 4 (1998) 1570-1580
21. Sieber P. An improved method for anchoring of 9-fluorenylmethoxycarbonyl-amino acids to 4-alkoxybenzyl alcohol resins. Tetrahedron Lett 28 (1987) 6147-6150
22. Applied Biosystems model 433A peptide synthesizers user's manual, Version 1.0, 1993.
23. Applied Biosystems model 433A peptide synthesizer research news, June 1993, 1-12.
24. Brouwer A.J., Monnee M.C.F., and Liskamp R.M.J. An efficient synthesis of N-protected beta-aminoethanesulfonyl chlorides: versatile building blocks for the synthesis of oligopeptidosulfonamides. Synthesis 11 (2002) 1579-1584
25. Janssen M., Frielink C., Dijkgraaf I., Oyen W., Edwards D.S., Rajopadhye M., et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm 19 (2004) 399-404
26. 50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations. J Pharmacol Toxicol Methods 46 (2002) 61-71
27. Cheng H.C. The influence of cooperativity on the determination of dissociation constants: examination of the Cheng-Prusoff equation, the Scatchard analysis, the Schild analysis and related power equations. Pharmacol Res 50 (2004) 21-40
28. 3 in complex with an Arg-Gly-Asp ligand. Science 296 (2002) 151-155
29. 3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 71 (1997) 320-324
30. 64Cu-labeled RGD peptide. Bioconjug Chem 15 (2004) 41-49
31. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31 (2004) 11-19
32. 3-integrin expression. J Nucl Med 45 (2004) 1776-1783